[go: up one dir, main page]

MX2011012017A - Nuevos derivados azaciclicos como inhibidores de lipasa sensible a las hormonas (hsl). - Google Patents

Nuevos derivados azaciclicos como inhibidores de lipasa sensible a las hormonas (hsl).

Info

Publication number
MX2011012017A
MX2011012017A MX2011012017A MX2011012017A MX2011012017A MX 2011012017 A MX2011012017 A MX 2011012017A MX 2011012017 A MX2011012017 A MX 2011012017A MX 2011012017 A MX2011012017 A MX 2011012017A MX 2011012017 A MX2011012017 A MX 2011012017A
Authority
MX
Mexico
Prior art keywords
spiroderivatives
azacyclic
hsl inhibitors
hsl
inhibitors
Prior art date
Application number
MX2011012017A
Other languages
English (en)
Inventor
Jean Ackermann
Werner Neidhart
Daniel Hunziker
Tanja Schulz-Gasch
Matthias Nettekoven
Aurelia Conte
Stanely Wertheimer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2011012017A publication Critical patent/MX2011012017A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Los compuestos de la fórmula (I) (ver fórmula (I)) así como sus sales farmacéuticamente aceptables pueden utilizarse en forma de composiciones farmacéuticas, en la que n, m, A, R1 y R2 tienen los significados definidos en la reivindicación 1. Los compuestos son útiles como inhibidores HSL para el tratamiento de la diabetes, la dislipidemia, la aterosclerosis o la obesidad.
MX2011012017A 2009-05-12 2010-05-10 Nuevos derivados azaciclicos como inhibidores de lipasa sensible a las hormonas (hsl). MX2011012017A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09160026 2009-05-12
PCT/EP2010/056307 WO2010130665A1 (en) 2009-05-12 2010-05-10 Azacyclic spiroderivatives as hsl inhibitors

Publications (1)

Publication Number Publication Date
MX2011012017A true MX2011012017A (es) 2011-12-06

Family

ID=42269304

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011012017A MX2011012017A (es) 2009-05-12 2010-05-10 Nuevos derivados azaciclicos como inhibidores de lipasa sensible a las hormonas (hsl).

Country Status (15)

Country Link
US (1) US8329904B2 (es)
EP (1) EP2430023B1 (es)
JP (1) JP5542916B2 (es)
KR (1) KR101438263B1 (es)
CN (1) CN102421777A (es)
AR (1) AR076666A1 (es)
AU (1) AU2010247472A1 (es)
BR (1) BRPI1015038A2 (es)
CA (1) CA2760340A1 (es)
ES (1) ES2450119T3 (es)
IL (1) IL214352A0 (es)
MX (1) MX2011012017A (es)
SG (1) SG175298A1 (es)
TW (1) TW201043629A (es)
WO (1) WO2010130665A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011009059A2 (en) * 2009-07-17 2011-01-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of treating or preventing cancer
US8258158B2 (en) * 2009-09-11 2012-09-04 Hoffmann-La Roche Inc. HSL inhibitors useful in the treatment of diabetes
US8097634B2 (en) 2010-04-15 2012-01-17 Hoffmann-La Roche Inc. Azacyclic derivatives
GB201007789D0 (en) * 2010-05-10 2010-06-23 Glaxo Group Ltd Novel Compound
GB201007791D0 (en) * 2010-05-10 2010-06-23 Glaxo Group Ltd Novel compounds
US8552024B2 (en) * 2010-08-13 2013-10-08 Hoffman-La Roche Inc. Azacyclic compounds
US8722721B2 (en) * 2011-03-16 2014-05-13 Hoffmann-La Roche Inc. SEC-hydroxycyclohexyl derivatives
US8703807B2 (en) * 2011-03-17 2014-04-22 Hoffmann-La Roche Inc. Azaspirodecanone compounds
US8809384B2 (en) * 2011-03-25 2014-08-19 Hoffmann-La Roche Inc. Azaspirodecanone compounds
US8497288B2 (en) 2011-05-09 2013-07-30 Hoffmann-La Roche Inc. Hexahydropyrroloimidazolone compounds
CN105073111A (zh) * 2012-10-11 2015-11-18 默沙东公司 用作gpr120激动剂的取代的螺哌啶基化合物
HRP20190613T1 (hr) 2013-01-29 2019-06-28 Aptinyx Inc. Spiro-laktam modulatori nmda receptora i njihove uporabe
CN103408573B (zh) * 2013-07-12 2015-12-23 上海工程技术大学 硼酸衍生物及其制备方法和应用
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
ES2886766T3 (es) 2015-03-31 2021-12-20 Enanta Pharm Inc Derivados del ácido biliar como agonistas de FXR/TGR5 y métodos de uso de estos
WO2017189652A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
US10080742B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2017189663A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
US10149835B2 (en) 2016-05-18 2018-12-11 Elmore Patent Law Group, P.C. Isoxazole derivatives as FXR agonists and methods of use thereof
US10144729B2 (en) 2016-05-18 2018-12-04 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
WO2017201152A1 (en) 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
PE20190503A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores del receptor nmda espiro-lactam y uso de los mismos
BR112019001921A2 (pt) 2016-08-01 2019-05-14 Aptinyx Inc. moduladores do receptor nmda de espiro-lactama e seus usos
MX388786B (es) 2016-08-01 2025-03-20 Aptinyx Inc Moduladores nmda espiro-lactam y métodos de uso de los mismos.
JP2019537557A (ja) 2016-10-04 2019-12-26 エナンタ ファーマシューティカルズ インコーポレイテッド Ｆｘｒアゴニストとしてのイソキサゾール類似体およびその使用方法
WO2018081285A1 (en) * 2016-10-26 2018-05-03 Enanta Pharmaceuticals, Inc. Urea-containing isoxazole derivatives as fxr agonists and methods of use thereof
KR102765806B1 (ko) * 2017-09-05 2025-02-10 블랙손 테라퓨틱스, 인크. 바소프레신 수용체 길항제 및 그와 관련된 제품 및 방법
WO2019118571A1 (en) 2017-12-12 2019-06-20 Enanta Pharmaceuticals, Inc. Isoxazole analogs as fxr agonists and methods of use thereof
WO2019152687A1 (en) 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
US10829486B2 (en) 2018-02-14 2020-11-10 Enanta Pharmacueticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
CN109503578A (zh) * 2018-12-17 2019-03-22 上海合全药物研发有限公司 1-氧亚基-2,8-二氮杂螺[4.5]癸烷-4-甲酸乙酯-8-甲酸叔丁酯合成方法
BR112021018864A2 (pt) 2019-03-29 2021-11-30 Sumitomo Chemical Co Composto heterocíclico e composição de controle de praga artrópode nociva contendo o mesmo
US11555032B2 (en) 2019-05-13 2023-01-17 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10247680B4 (de) 2002-10-12 2005-09-01 Aventis Pharma Deutschland Gmbh Neue bicyclische Inhibitoren der Hormon Sensitiven Lipase
WO2005084667A1 (en) 2004-03-03 2005-09-15 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
EP1802623A1 (en) * 2004-10-12 2007-07-04 Novo Nordisk A/S 11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds
NZ554906A (en) * 2004-11-10 2011-01-28 Incyte Corp Lactam compounds and their use as pharmaceuticals
TW200804382A (en) 2005-12-05 2008-01-16 Incyte Corp Lactam compounds and methods of using the same
US20070208001A1 (en) * 2006-03-03 2007-09-06 Jincong Zhuo Modulators of 11- beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same

Also Published As

Publication number Publication date
CN102421777A (zh) 2012-04-18
US20100292212A1 (en) 2010-11-18
JP2012526154A (ja) 2012-10-25
IL214352A0 (en) 2011-09-27
TW201043629A (en) 2010-12-16
JP5542916B2 (ja) 2014-07-09
SG175298A1 (en) 2011-11-28
ES2450119T3 (es) 2014-03-24
AR076666A1 (es) 2011-06-29
AU2010247472A1 (en) 2011-09-29
EP2430023A1 (en) 2012-03-21
US8329904B2 (en) 2012-12-11
BRPI1015038A2 (pt) 2016-04-12
EP2430023B1 (en) 2013-12-11
WO2010130665A1 (en) 2010-11-18
CA2760340A1 (en) 2010-11-18
KR101438263B1 (ko) 2014-09-05
KR20120035160A (ko) 2012-04-13

Similar Documents

Publication Publication Date Title
MX2011012017A (es) Nuevos derivados azaciclicos como inhibidores de lipasa sensible a las hormonas (hsl).
IN2012DN03337A (es)
IN2012DN01233A (es)
MX2009007180A (es) Agonistas del receptor acoplado a la proteina g de la piperidina.
JO2892B1 (en) CYP inhibitors 17
MX2010003366A (es) Derivados de piperidina y piperazina para el tratamiento de tumores.
UA102310C2 (ru) Гетероциклические сульфонамиды, их применение и фармацевтические композиции
MX2010005824A (es) Derivados de aminotiazol.
GEP20125487B (en) Organic compounds and their use
MY149648A (en) Carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
MX2012006805A (es) Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa.
MX2011011854A (es) Dihidropirimidinonas para uso como inhibidores de la bace2.
MX2007003546A (es) Derivados de indozolona como inhibidores de 11-beta- hidroxiesteroide-deshidrogenasa.
TN2012000152A1 (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
TN2012000248A1 (en) Novel spiropiperidine compounds
IN2012DN03182A (es)
TN2011000438A1 (en) Compounds as bradykinin b1 antagonists
WO2011047055A3 (en) Novel mek inhibitors, useful in the treatment of diseases
IN2012DN01232A (es)
MX2010006108A (es) Inhibidores de estearoil-coa-desaturasa.
IN2012DN00765A (es)
MX2010005714A (es) Compuestos de piridina.
WO2009126861A3 (en) Triazolopyridine compounds useful as dgat1 inhibitors
MX2007003913A (es) Alquil-piridinas como inhibidores de 11 beta para diabetes.
MX346090B (es) Derivados de pirrolidina usados como inhibidores de catepsina.

Legal Events

Date Code Title Description
FG Grant or registration